
Barinthus Bio and Clywedog Therapeutics announce merger
Immunology and inflammation company Barinthus Biotherapeutics and private company Clywedog Therapeutics will merge to target metabolic and autoimmune diseases, the companies have announced. The combined company, named Clywedog Therapeutics, will now advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. The portfolio includes three differentiated, clinical stage… Read More





